Dupixent 300 MG/2 ML pen 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26F9LA4
- Awardee
-
Amerisourcebergen Drug Corp UEI KABZK8W6PQT3 Part of Cencora, Inc.
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $29,883
Award facts
- Contract value 100% obligated
- $29,883.40 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
This delivery order, awarded January 13, 2026, represents a $29,883.40 firm fixed-price purchase of Dupixent 300 mg/2 ml pen injections (2 ml vials) from Amerisourcebergen Drug Corp, a subsidiary of Cencora, Inc. The contract was issued without a set-aside designation through the Defense Logistics Agency (DLA), with performance to be completed by January 14, 2026, at the vendor's facility in Conshohocken, Pennsylvania. Dupixent is a biologic medication used to treat moderate-to-severe atopic dermatitis, eosinophilic esophagitis, and certain asthma conditions, indicating this delivery supports military healthcare treatment requirements.
This delivery order is issued under Amerisourcebergen's comprehensive Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.99 million through December 2026. The parent IDC functions as a global pharmaceutical prime vendor vehicle enabling the delivery of an extensive range of specialty medications, brand-name and generic drugs, and medical supplies to support Department of Defense healthcare programs worldwide, including military treatment facilities, the Defense Health Agency, and the U.S. Coast Guard. The non-competitive, single-award structure of the underlying IDC reflects Amerisourcebergen's established capability and strategic role in the federal pharmaceutical supply chain.
Quick answers
Who was awarded contract SPE2DR26F9LA4?
SPE2DR26F9LA4 was awarded to Amerisourcebergen Drug Corp by Defense Logistics Agency (Department of Defense) on January 13, 2026.
How much is contract SPE2DR26F9LA4 worth?
The government has obligated $29,883 on SPE2DR26F9LA4.
Is contract SPE2DR26F9LA4 an order under another contract?
Yes. SPE2DR26F9LA4 is a delivery order under SPE2DR25D2206, an indefinite delivery contract.
Was contract SPE2DR26F9LA4 competed?
The extent of competition for SPE2DR26F9LA4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award